Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Gemcitabine, Cisplatin, Nab-Paclitaxel, and Durvalumab in Locally Advanced or Metastatic Gallbladder Cancer

NCT06591650 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06591650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06591650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Gemcitabine, Cisplatin, Nab-Paclitaxel, and Durvalumab in Locally Advanced or Metastatic Gallbladder Cancer
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
October 24, 2024
Completion date
October 30, 2027
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gallbladder cancer unresectable